Oral News and Research

RSS

Genzyme third quarter revenue increases to $1.0 billion

Genzyme Corp. today reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter. Earnings growth in the third quarter was also driven by strong revenue from Lumizyme™ (alglucosidase alfa) and cost reduction measures.

21 Oct 2010

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from seven hospital Institutional Review Boards in India to begin enrollment of subjects for a Phase III clinical trial of Multikine, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

21 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

New model for rural clinics in underserved areas

The University of Maryland Dental School Clinic, Perryville is a new model for rural clinics in underserved areas across the country, says Christian S. Stohler, DMD, DrMedDent, dean of the Dental School in Baltimore.

20 Oct 2010

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

The US Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate), Boehringer Ingelheim's novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) marking the first approval of a new oral anticoagulant in the U.S. in more than 50 years.

20 Oct 2010

Turmeric component enhances chemotherapy's suppression of head and neck cancer

Curcumin, the major component in the spice turmeric, when combined with the drug Cisplatin enhances the chemotherapy's suppression of head and neck cancer cell growth, researchers with UCLA's Jonsson Cancer Center have found.

20 Oct 2010

Experts at Ninth International Symposium discuss health effects and safety of S-equol

The latest research into the health effects and safety of a soy-based compound called S-equol was described in talks and presentations by experts at a special session on Tuesday, Oct. 19 during the Ninth International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment, held Oct. 16 to 19 in Washington, D.C.

20 Oct 2010

Salix acquires rights to colon cancer screening agent from Photocure

Salix Pharmaceuticals, Ltd. today announced that the Company has acquired rights to Lumacan™ from Photocure, a Norwegian specialty pharmaceutical company. Lumacan is a novel agent designed to assist in the detection of precancerous and cancerous lesions in the colon.

20 Oct 2010

Osteoporosis drug heals bone wounds in gum disease patients

A drug marketed to grow bone in osteoporosis patients also works to heal bone wounds in gum disease patients, a University of Michigan study suggests.

20 Oct 2010

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

The U.S. Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate) capsules to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).

20 Oct 2010

En Ze Jia Shi Pharmaceuticals receives patent for controlled-release oral gliclazide

Lotus Pharmaceuticals, Inc.a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China announced today that its wholly owned subsidiary, En Ze Jia Shi Pharmaceuticals, has been issued a patent by the State Intellectual Property Office of the People's Republic of China for controlled-release oral gliclazide. The patent covers the composition and preparation methods for the drug through 2030.

20 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

First Edition: October 19, 2010

Today's major health policy headlines include reports about the latest developments in Virginia's court challenge against the health law, a U.S. government lawsuit targeting Michigan Blue Cross Blue Shield for anti-trust activities and a study about the Department of Health and Human Services' Hospital Compare.

19 Oct 2010

HOYA ConBio's dentistry lasers to be featured at LVI's teaching facilities through 2013

HOYA ConBio™, a global leader in dental and aesthetic lasers, today announced an extension of its sponsorship agreement with the Las Vegas Institute for Advanced Dental Studies (LVI), the pioneer in live-patient, post-graduate dental training. The agreement ensures that VersaWave™ and DioDent™ Micro 980 lasers will continue to be featured at LVI's advanced teaching facilities through 2013.

19 Oct 2010

ADHA and GSK emphasize importance of proper brushing as key to maintaining oral health

With the theme "Healthy Habits are Easier than You Think" for its National Dental Hygiene Month (NDHM) celebration this October, the American Dental Hygienists' Association (ADHA), in collaboration with GlaxoSmithKline (GSK), makers of Aquafresh®, emphasizes the importance of proper brushing as a key to maintaining excellent oral health.

19 Oct 2010

Peer partner program helps diabetic patients to manage their conditions

Phone calls with a peer facing the same self-management challenges helped diabetes patients manage their conditions and improved their blood sugar levels better than those who used traditional nurse care management services alone, according to research from the University of Michigan Health System.

19 Oct 2010

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.

19 Oct 2010

Federal judge says he'll rule on Virginia's health law challenge by year's end

Bloomberg: "A federal judge in Virginia said he'll rule by yearend whether President Barack Obama's health care overhaul is constitutional, adding that his decision will be a 'brief stop' in the case on its way to the Supreme Court." U.S. District Court Judge Henry E. Hudson heard arguments today in Richmond, Virginia, about whether the health law's requirement for individuals to buy health insurance is congressional overreaching.

19 Oct 2010

Study finds IAP enzyme maintains normal microbial population in gastrointestinal system

An enzyme that keeps intestinal bacteria out of the bloodstream may also play an important role in maintaining the normal microbial population of the gastrointestinal system.

19 Oct 2010

Elorac acquires world-wide rights to Cidoxepin

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, is pleased to announce that it has acquired world-wide rights to the active agent Cidoxepin from Gideon Pharmaceuticals. Cidoxepin is the cis-isomer of the widely prescribed tricyclic compound doxepin.

19 Oct 2010

Oral News and Research

Genzyme third quarter revenue increases to $1.0 billion

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

New model for rural clinics in underserved areas

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

Turmeric component enhances chemotherapy's suppression of head and neck cancer

Experts at Ninth International Symposium discuss health effects and safety of S-equol

Salix acquires rights to colon cancer screening agent from Photocure

Osteoporosis drug heals bone wounds in gum disease patients

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

En Ze Jia Shi Pharmaceuticals receives patent for controlled-release oral gliclazide

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

First Edition: October 19, 2010

HOYA ConBio's dentistry lasers to be featured at LVI's teaching facilities through 2013

ADHA and GSK emphasize importance of proper brushing as key to maintaining oral health

Peer partner program helps diabetic patients to manage their conditions

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

Federal judge says he'll rule on Virginia's health law challenge by year's end

Study finds IAP enzyme maintains normal microbial population in gastrointestinal system

Elorac acquires world-wide rights to Cidoxepin

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News